Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 98

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 98
---
 that our Argentine Wet -Labactivities, particularly those related to research and development, achieve self -sufficiencyby being funded through revenues generated in Argentina. Our goal is for the Argentine Wet -Labto become self -sustainingby the end of 2025, supported by anticipated growth in revenue from Argentina, where we are working closely with our shareholder and commercial partner in Argentina, CIBIC, to expand in line with the growing demand for local genomics services. However, until we achieve the necessary revenue levels in Argentina, our operations will continue to require external funding sources, and there is no guarantee that revenues in Argentina will meet our self -fundingobjectives within our projected timelines. Additionally, if we are unsuccessful in leveraging the scientific and genetics talent available in Argentina or in aligning our operations to the growth of the local genomics industry, we may face additional costs or funding needs. This reliance on future revenues to support our research and development could affect our business, results of operations, financial condition, and growth prospects. If new regulations emerge regarding telemedicine services, biological sample logistics, or data transfer, we may incur additional compliance costs or face operational disruptions. One of our key differentiators will be the ability to provide telemedicine services and biological sample logistics for the Latin American market. We will prioritize establishing robust systems for our telemedicine services and biological sample logistics with the general health regulations of each country where we operate, with no specific regulatory framework governing these areas. Our immediate priority for biological sample logistics is to establish seamless operations coinciding with the launch of our processing hub in Mexico. This hub will streamline sample handling and logistics across the region. Following this, we will introduce telemedicine services as part of our broader commercialization strategy. These services will comply with regulatory requirements and address the healthcare needs specific to each market. However, if new regulatory frameworks emerge that apply to telemedicine services, the handling of biological samples, or the cross -bordertransfer of biological data, we may need to adjust our operations to adapt to these regulations. Any new regulations could be more stringent than those in place in the countries where our tests are developed and used, potentially affecting the scope or method of service delivery. Further, new regulations may mandate additional oversight regarding the professionals authorized to conduct tests, analyze results, or sign reports. Such requirements could conflict with our existing agreements with distribution partners, laboratories, and healthcare professionals. In that case, we may be forced to renegotiate existing agreements, potentially incurring additional costs and delays. If we are unable to